Idiopathic Pulmonary Fibrosis - 31 Studies Found
| Completed |
: Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF). : Idiopathic Pulmonary Fibrosis : 2025-08-03 : Nitric oxide gas for inhalation |
| COMPLETED |
: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF : Idiopathic Pulmonary Fibrosis : 2025-08-03 : Intravenous administration of a starting dose of the monoclonal antibody |
| COMPLETED |
: Efficacy of Steroid Pulse Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF) Admitted in ER : Idiopathic Pulmonary Fibrosis With Acute Exacerbation : 2025-08-03 : Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days ? 0.5 mg/kg 7 days ? 0.25 mg kg 7 days |
| COMPLETED |
: Study Evaluating INS018_055 Administered Orally to Subjects with Idiopathic Pulmonary Fibrosis (IPF) : Idiopathic Pulmonary Fibrosis (IPF) : 2025-08-03 : Pharmaceutical formulation: CapsulesMode of Administration: Oral |
| COMPLETED |
: Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis : Idiopathic Pulmonary Fibrosis, Acute Fatal Form : 2025-08-03 : TPE x 9, rituximab x 2, IVIG x 4. See arm/group descriptions for additional details. |
| COMPLETED |
: A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) : Idiopathic Pulmonary Fibrosis : 2025-08-03 : BI 1015550 |
| COMPLETED |
: IPF MHealth Exercise Study : Idiopathic Pulmonary Fibrosis : 2025-08-03 : 3x/week home walking protocol, 2x/week resistance exercise program |
| COMPLETED |
: Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT : Idiopathic Pulmonary Fibrosis : 2025-08-03 : 7mCi (range 6-9mCi) [18F]FP-R01-MG-F2 will be administered |
| COMPLETED |
: Evaluation of the Value of 18F-Fluoromisonidazole (18F-FMISO) Positron Emission Tomography Hypoxia Imaging in Idiopathic Pulmonary Fibrosis : Idiopathic Pulmonary Fibrosis : 2025-08-03 :
|
| COMPLETED |
: A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF) : Idiopathic Pulmonary Fibrosis : 2025-08-03 : REGEND001: 1-1.5�10^6 bronchial basal cells/kg administrated by bronchoscopy. |